Table 1 Clinicopathological features and CAV1 expression in CAFs.

From: Correction: Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma

 

Total (n = 158)

CAV1 expression in CAFs

p value

Negative (n = 80)

Positive (n = 78)

Age (yr)

67.3 ± 10.3

65.8 ± 10.7

68.7 ± 9.7

0.080

Sex

   

0.434

  Male

88 (55.7%)

47 (58.7%)

41 (52.6%)

 

  Female

70 (44.3%)

33 (41.3%)

37 (47.4%)

 

BMI

22.8 ± 3.2

22.4 ± 3.3

23.2 ± 3.1

0.117

CEA (ng/mL)

3.0 (0.6–1692)

2.9 (0.6–1692)

3.1 (0.7–150.1)

0.123

CA19-9 (ng/mL)

36.0 (0–74,079)

22.8 (0.1–36,230)

54.1 (0–74,079)

0.001

PLT

19.8 (5.1–296)

19.6 (5.4–159)

20.7 (5.1–296)

0.953

Total bilirubin (mg/dL)

0.7 (0.1–13.4)

0.7 (0.1–1.6)

0.7 (0.2–13.4)

0.548

Albumin (g/dL)

4.1 (2.6–5.1)

4.1 (3.1–5.1)

4.1 (2.6–4.9)

0.615

Tumor size (mm)

39 (1–180)

35 (1–120)

40 (2.5–180)

0.337

pT

   

0.046

  T0–2

109 (69.0%)

61 (76.3%)

48 (61.5%)

 

  T3, 4

49 (31.0%)

19 (23.7%)

30 (38.5%)

 

pN

   

0.004

  No

128 (81.0%)

72 (90.0%)

56 (71.8%)

 

  Yes

30 (19.0%)

8 (10.0%)

22 (28.2%)

 

Operating time (min)

369.9 ± 131.6

385.7 ± 137.6

353.7 ± 123.8

0.126

Blood loss (mL)

467.5 (2–5140)

437.5 (5–2897)

560 (29–5140)

0.105

Differentiation

   

0.337

  Well/Mod

107 (67.7%)

57 (71.3%)

50 (64.1%)

 

  Poor

51 (32.3%)

23 (28.7%)

28 (35.9%)

 

Postoperative chemotherapy

   

0.523

  No

117 (74.1%)

61 (76.3%)

56 (71.8%)

 

  Yes

41 (25.9%)

19 (23.7%)

22 (28.2%)

 
  1. CAV1 caveolin-1, CAFs cancer-associated fibroblasts, BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, pT pathological tumor stage, pN pathological nodal stage, Mod moderately, Poor poorly.
Back to article page